Department of Neurology, University Hospital Würzburg, Würzburg, Germany.
Section for Experimental Tumor Immunology, Department of Obstetrics and Gynecology, University Hospital of Würzburg, Würzburg, Germany.
Front Immunol. 2022 May 18;13:878771. doi: 10.3389/fimmu.2022.878771. eCollection 2022.
Parkinson's disease (PD) is a progressive and debilitating chronic disease that affects more than six million people worldwide, with rising prevalence. The hallmarks of PD are motor deficits, the spreading of pathological α-synuclein clusters in the central nervous system, and neuroinflammatory processes. PD is treated symptomatically, as no causally-acting drug or procedure has been successfully established for clinical use. Various pathways contributing to dopaminergic neuron loss in PD have been investigated and described to interact with the innate and adaptive immune system. We discuss the possible contribution of interconnected pathways related to the immune response, focusing on the pathophysiology and neurodegeneration of PD. In addition, we provide an overview of clinical trials targeting neuroinflammation in PD.
帕金森病（PD）是一种进行性和使人虚弱的慢性疾病，影响着全球超过 600 万人，且患病率还在不断上升。PD 的特征是运动缺陷、病理性α-突触核蛋白在中枢神经系统中的扩散以及神经炎症过程。PD 是对症治疗，因为没有因果关系的药物或程序被成功确立用于临床使用。已经研究并描述了各种导致 PD 中多巴胺能神经元丧失的途径，这些途径与先天和适应性免疫系统相互作用。我们讨论了与免疫反应相关的相互关联的途径的可能贡献，重点是 PD 的病理生理学和神经退行性变。此外，我们还概述了针对 PD 中神经炎症的临床试验。
